Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Sandoz GmbH, Biochemiestrasse 10, 6250 Kundl, Austria
Rimactane 300 mg Capsules.
| Pharmaceutical Form |
|---|
|
Capsules. Opaque, two-piece, hard gelatine capsule, reddish-brown in colour, marked with ‘NG 300’. |
The active ingredient is 3-(4-Methyl-1-piperazinyliminomethyl) rifamycin SV.
One capsule contains 300 mg rifampicin Ph. Eur.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Rifampicin |
Rifampicin is an active bactericidial antituberculosis drug which is particularly active against the rapidly growing extracellular organisms and also has bactericidial activity intracellularly. Rifampicin inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme. |
| List of Excipients |
|---|
|
The capsules contain: Calcium stearate |
The capsules are opaque, two-piece, hard gelatine capsule size 1, reddish-brown in colour, marked with the monogram NG on each half and the code 300, and come in securitainers of 100 and PVC/PE/PVdC blister packs of 60.
Sandoz GmbH, Biochemiestrasse 10, 6250 Kundl, Austria
PL 04520/0043
1 February 2000
| Drug | Countries | |
|---|---|---|
| RIMACTANE | Hong Kong, Malta, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
